Update from Dr. Stupp on 2yr survival now that NOVO-TTF is approved in both rGBM and nGBM setting:
https://
www.youtube.com/watch?v=ajnk3XfLm60 2yr survival went up from 30% to 43%. Any researchers still quoting the 2005 Stupp data is probably IMO just trying to make their research look a little better. That is what historical data is useful for.
43% of 331 patients is about 142 patients who should still be alive in this DCVAX-L trial if they were also doing the TTF treatment. So having 98patients still alive after 2 yrs falls within the range of "normal" and not "exceptional" at this point in time.
JMHO